Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Valion BioVBIO +2.76%23 Buyback Yield % is 0.00 as of Aug. 03, 2026. GuruFocus rates VBIO with a GF Score™ of 23/100. The stock has 1 warning sign investors should review. Among 735 Biotechnology companies, Valion Bio ranks worse than 136054.29% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Valion Bio's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
VBIO vs ZVSA, LYRA, ATXI: Buyback Yield % Comparison
For the Biotechnology subindustry, Valion Bio's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Valion Bio Buyback Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Valion Bio's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Valion Bio's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Valion Bio (VBIO) has a Buyback Yield % of 0.00 as of Aug. 03, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Valion Bio and its competitors. According to the industry distribution chart, Valion Bio ranks #999999 out of 735 companies in the Biotechnology industry.
Is Valion Bio's Buyback Yield % too high?
Valion Bio's current Buyback Yield % is 0.00. Based on the distribution chart, Valion Bio ranks #999999 out of 735 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Valion Bio has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does Valion Bio's Buyback Yield % compare to ZVSA and LYRA?
According to the Biotechnology industry distribution chart, Valion Bio ranks #999999 out of 735 companies for Buyback Yield %. This places Valion Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Valion Bio and its competitors. Valion Bio's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Valion Bio stock overvalued right now?
Valion Bio (VBIO) has a current Buyback Yield % of 0.00. The current Buyback Yield % is 0.00. Valion Bio's overall GF Score™ is 23/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Valion Bio (VBIO), the current Buyback Yield % is 0.00 as of Aug. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Valion Bio Inc is a late-stage biopharmaceutical company developing biologics that activate innate immune pathways for cytoprotection and immune modulation. Its main candidate, Entolimod, is a TLR5 agonist and also advances Entolasta, a next-generation TLR5 agonist, and targets the neutropenia oncology supportive care market.
23GF Score
Get the complete analysis for VBIO
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
VBIO has been successfully added to your 
